PMA device
ARCHITECT Total PSA, Alinity i Total PSA
Abbott Laboratories · Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF, Class III) · First FDA decision May 29, 2009, newest Oct 11, 2023Prostate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
8
Naming "ARCHITECT"
MAUDE reports
11,484
Brand "ARCHITECT", since 2015
PubMed studies
2,841
Mentioning "ARCHITECT"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ARCHITECT Total PSA, Alinity i Total PSA
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- ARCHITECT Total PSA, Alinity i Total PSAPMA supplement
P910007-S060 · Decided Oct 11, 2023 · 237 days after receipt · Normal 180 Day Track
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
- ARCHITECT Total PSAPMA supplement
P910007-S053 · Decided May 23, 2020 · 68 days after receipt · Normal 180 Day Track No User Fee
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
- ARCHITECT TOTAL PSAPMA supplement
P910007-S029 · Decided Jul 22, 2011 · 79 days after receipt · Normal 180 Day Track No User Fee
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: P910007-S017
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Specific AntigenNational determinationOn the books190.31Updated Oct 1, 2026
- Prostate Specific Antigen (Inclusion of ICD-9-CM Code 600.01 for BPH with Urine Obstruction)Coding analysisReview closedCAG-00232NUpdated Sep 15, 2026
- Prostate Specific Antigen (Addition of ICD-9-CM 600.00, Hypertrophy (benign) of Prostate Without Urinary Obstruction, as a covered indication)Coding analysisReview closedCAG-00326NUpdated Sep 15, 2026
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "ARCHITECT", any status and sponsor, newest update first.
Erasmus Medical CenterAcademic, hospital or other
NCT07435987 · 25 participants (planned) · Start Jul 22, 2026 · Primary completion Dec 2027
Device: ARCHITECT applicator · For: Locally Advanced Cervical Cancer; Uterine Carcinoma
Sites: Rotterdam, Netherlands
- Multicenter, Prospective Study to Determine the Performance and Safety of the New M-HA30 Architect Device on the Quality of the Skin: HEBE8 StudyPivotal-lookingCompleted
Laboratoires FILLMEDNot on our public-company list
NCT07007351 · 285 participants · Start Mar 19, 2023 · Primary completion Apr 13, 2024
Device: Intradermal injection · For: Skin Aging
Sites: Paris, France
- Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site SettingsPivotal-lookingCompleted
bioLytical LaboratoriesNot on our public-company list
NCT06368479 · 1,400 participants · Start Mar 19, 2024 · Primary completion Jul 19, 2024
Device: iStatis HBsAg Test · For: Hepatitis B; Hepatitis B Infection
Sites: Hillcrest, South Africa
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ARCHITECT", and for the whole product code for context.
This brand
11,484 reports: 11,248 malfunction, 232 injury, 4 death
Whole product code MTF
390 reports: 373 malfunction, 17 injury, 0 death
Newest reports for this brand
3016438761-2026-00599 · Received Oct 29, 2026 · Event dated Oct 20, 2026
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: Low Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- ARCHITECT STAT High Sensitive Troponin-IMalfunction
Abbott Ireland Diagnostics Division
3005094123-2026-00537 · Received Oct 29, 2026 · Event dated Oct 20, 2026
Device type: Immunoassay Method, Troponin Subunit (MMI)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- ARCHITECT i1000SR Processing ModuleMalfunction
3016438761-2026-00602 · Received Oct 29, 2026 · Event dated Oct 12, 2026
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ARCHITECT"[tiab]. The summary above synthesizes these.
- Architect Glasses.
Schweitzer M · J Am Coll Radiol · 2018
- The organoid architect.
Sinha G · Science · 2017Biography, Historical Article
- C. Thomas Caskey (1938-2022).
Ballabio A, Zoghbi H · Science · 2022
- ARCHITECT anti-HCV assay.
Myrmel H, Navaratnam V, Asjø B · J Clin Virol · 2005Comment, Letter
- Architect: A tool for aiding the reconstruction of high-quality metabolic models through improved enzyme annotation.
Nursimulu N, Moses AM, Parkinson J · PLoS Comput Biol · 2022Research Support, Non-U.S. Gov't
- An architect's response.
Pangrazio JR · HERD · 2009Comment
- Architect/engineer giants.
Consult Specif Eng · 1987Directory
- Rinaldo Bellomo: relentless architect of modern intensive care.
Forni LG, Hodgson C, Prowle JR · Intensive Care Med · 2025Editorial
- Biosynthesis: A carbonate architect emerges.
Sun Y · Nat Chem Biol · 2014News, Comment
- Modified ARCHITECT® serologic assays enable plasma-level performance from dried blood spot samples.
Holzmayer V, Anderson M, Ndembi N, et al. · Biotechniques · 2022Research Support, Non-U.S. Gov't
- IRF8 as durable architect of the microglial chromatin landscape.
Frosch M, Prinz M · Nat Immunol · 2024
- Always a Nurse: The Nurse Architect.
Felker T · Nurs Adm Q · 2020
Other devices of this type
Also filed under product code MTF.
- Elecsys total PSA, total PSA CalSet IIRoche Diagnostics Corp. · PMA 2023
- Access Hybritech PSABeckman Coulter, Inc. · PMA 2024
- Dimension Vista Tpsa AssaySiemens Healthcare Diagnostics · PMA 2016
- Atellica IM Total PSA II (tPSAII)Siemens Healthcare Diagnostics, Inc. · PMA 2026
- Advia Centaur Psa AssaySiemens Healthcare Diagnostics · PMA 2017
- Axsym Total PsaAbbott Laboratories · PMA 2011
- Abbott Architect Total PsaAbbott Laboratories · PMA 2011
- Immulite/Immulite 1000/IMMULITE 2000/IMMULITE 2500 Psa & 3RD Generation PsaSiemens Healthcare Diagnostics, Inc. · PMA 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.